Últimas noticias sobre TG Therapeutics (NASDAQ:TGTX) Bolsa

TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics Inc

B. Riley notes TG Therapeutics (TGTX) reported Q3 results, pointing to strong 15% sequential quarter-over-quarter growth in Briumvi U.S. sales, res...

B. Riley remains a buyer of TG Therapeutics on weakness following Q3 results

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), retaining the price target of $38....

TG Therapeutics: Strong Financial Performance and Strategic Expansion Drive Buy Rating

TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell

TG Therapeutics ( ($TGTX) ) has released its Q3 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors. TG The...

TG Therapeutics Boosts Revenue Outlook Amidst Growth

Bullish option flow detected in TG Therapeutics (TGTX) with 2,340 calls trading, 1.0x expected, and implied vol increasing almost 2 points to 62.65...

TG Therapeutics call volume above normal and directionally bullish

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

Bullish option flow detected in TG Therapeutics (TGTX) with 5,007 calls trading, 2x expected, and implied vol increasing almost 2 points to 62.81%....

Dominic Walsh, a business reporter who previously covered the leisure and drinks industry for The Times from 1997 to 2024, stated in post to X: "Th...

Reporters tweets about 'vague whispers' of bid interest in TG Therapeutics

Unusual total active option classes on open include: Disney (DIS), Advance Auto Parts (AAP), TG Therapeutics (TGTX), MGM Resorts (MGM), ARK Genomic...

Unusually active option classes on open November 14th

JPMorgan raised the firm's price target on TG Therapeutics (TGTX) to $43 from $30 and keeps an Overweight rating on the shares. The firm says that ...

TG Therapeutics price target raised to $43 from $30 at JPMorgan

ARKG

AZNCF

CAVA

RKLB

SHOP

TGTX

ZETA

Earnings

News

Press Releases

TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

ADMA

ADNT

AMCX

CHCT

CSWI

CVGW

DELL

EHAB

ERIE

ETSY

HELE

HLNE

INSP

MERC

PGNY

PLTR

RILY

SPGI

TGNA

VNOM

VREX

WOLF

ZEUS

Arcellx

ADMA Biologics

Alkermes

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Roivant Sciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Telix Pharmaceuticals Limited - American Depositary Shares

Comments

TG Therapeutics

Noticias

Últimas noticias sobre TG Therapeutics (NASDAQ:TGTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL